Crossmark

PDLIM2 is a novel E5 ubiquitin ligase enhancer that stabilizes ROC1 and recruits the ROC1-SCF ubiquitin ligase to ubiquitinate and degrade NF-κB RelA

Published Online: 2024-07-30

Authors

Sun, Fan

Xiao, Gutian

Qu, Zhaoxia http://orcid.org/0000-0002-2769-9814
Funding

Funding for this research was provided by:

National Institutes of Health (R01 GM144890, R01 CA258614)

National Cancer Institute (R21 CA259706)

American Cancer Society (RSG-19-166-01-TBG)

American Lung Association (821321)

Tobacco-Related Disease Research Program (T33IR6461)
License Information

Text and Data Mining valid from 2024-07-30

Version of Record valid from 2024-07-30
More Information

Article History

Received: 17 March 2024

Accepted: 18 July 2024

First Online: 30 July 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current